The new guidelines include 10 recommendations spanning extended molecular testing, JAK inhibitor use, anemia management, and ...
As radiotherapy becomes more strategically integrated around CAR T-cell therapy in multiple myeloma, clinicians face a choice ...
In a phase 1 trial of patients with platinum-sensitive high-grade ovarian cancer, a personalized neoantigen vaccine plus ...
Nikolai Strusberg, MD, discussed how proton therapy and thyroid dose affect clinical hypothyroidism risk after ...
Erik Bengtsen, MD, shares a key depression screening question and explains when oncologists can start a low-dose ...
Al-Ola A. Abdallah, MD, highlights the data on etentamig, teclistamab/daratumumab, and iberdomide he found most impactful at IMS 2026.
Data from the phase 2/3 QUILT-3.032 trial support the expanded indication for nogapendekin alfa in BCG-unresponsive ...
Boccia, MD, FACP, discussed stopping therapy in patients with deep, sustained responses and the move toward fixed-duration ...
Practical guidance for starting belantamab: confirm eligibility, coordinate ophthalmology exams, manage reversible eye ...
The FDA has accepted a resubmitted biologics license application (BLA) for tabelecleucel (tab-cel; Ebvallo), with a proposed ...
Experts explain how myeloma regimens manage eye toxicity with baseline exams, dose holds, reductions, and longer belantamab ...
Erik Bengtsen, MD, shares a key depression screening question and explains when oncologists can start a low-dose antidepressant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results